Dimensional Fund Advisors LP Buys 34,512 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Dimensional Fund Advisors LP grew its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 354,835 shares of the company's stock after acquiring an additional 34,512 shares during the quarter. Dimensional Fund Advisors LP owned 0.85% of SI-BONE worth $4,974,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Mainstream Capital Management LLC bought a new stake in SI-BONE during the 4th quarter worth approximately $53,000. R Squared Ltd bought a new stake in shares of SI-BONE during the fourth quarter worth $73,000. KLP Kapitalforvaltning AS acquired a new stake in shares of SI-BONE during the fourth quarter worth $97,000. Proficio Capital Partners LLC bought a new stake in SI-BONE in the 4th quarter valued at $155,000. Finally, AlphaQuest LLC boosted its stake in SI-BONE by 13,950.6% in the 4th quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock worth $164,000 after purchasing an additional 11,579 shares during the period. Institutional investors and hedge funds own 98.11% of the company's stock.

Insider Transactions at SI-BONE

In related news, CEO Laura Francis sold 38,504 shares of SI-BONE stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total transaction of $661,498.72. Following the completion of the transaction, the chief executive officer now owns 302,958 shares in the company, valued at approximately $5,204,818.44. This trade represents a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. This represents a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,153 shares of company stock worth $935,040 in the last 90 days. Corporate insiders own 4.00% of the company's stock.

SI-BONE Stock Up 4.8%

SIBN stock traded up $0.91 during midday trading on Friday, hitting $19.79. The company's stock had a trading volume of 795,534 shares, compared to its average volume of 373,483. The company's fifty day moving average price is $14.74 and its 200 day moving average price is $14.97. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.03. The stock has a market capitalization of $843.35 million, a P/E ratio of -21.51 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. As a group, equities research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

SIBN has been the subject of a number of research reports. Truist Financial lifted their price target on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.